abrdn plc Boosts Holdings in Humana Inc. (NYSE:HUM)

abrdn plc boosted its position in shares of Humana Inc. (NYSE:HUM) by 15.2% in the fourth quarter, HoldingsChannel reports. The fund owned 125,860 shares of the insurance provider’s stock after purchasing an additional 16,612 shares during the quarter. abrdn plc’s holdings in Humana were worth $31,941,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. FNY Investment Advisers LLC lifted its position in Humana by 6,647.5% during the fourth quarter. FNY Investment Advisers LLC now owns 27,260 shares of the insurance provider’s stock valued at $6,916,000 after acquiring an additional 26,856 shares during the last quarter. PDT Partners LLC lifted its position in Humana by 190.0% during the third quarter. PDT Partners LLC now owns 4,060 shares of the insurance provider’s stock valued at $1,286,000 after acquiring an additional 2,660 shares during the last quarter. Secure Asset Management LLC purchased a new stake in Humana during the fourth quarter valued at approximately $244,000. Ontario Teachers Pension Plan Board lifted its position in Humana by 6.5% during the third quarter. Ontario Teachers Pension Plan Board now owns 1,173,535 shares of the insurance provider’s stock valued at $371,705,000 after acquiring an additional 71,910 shares during the last quarter. Finally, Swedbank AB lifted its position in Humana by 3.0% during the third quarter. Swedbank AB now owns 105,976 shares of the insurance provider’s stock valued at $33,567,000 after acquiring an additional 3,085 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Insider Activity at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.29% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on HUM shares. Truist Financial raised their price target on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a report on Monday, January 6th. Morgan Stanley raised their price target on shares of Humana from $288.00 to $301.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 17th. Piper Sandler raised their price target on shares of Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a report on Wednesday, January 15th. Bank of America raised shares of Humana from an “underperform” rating to a “neutral” rating and raised their price target for the stock from $247.00 to $308.00 in a report on Wednesday, November 6th. Finally, KeyCorp started coverage on shares of Humana in a report on Friday, October 11th. They issued a “sector weight” rating for the company. Nineteen analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $297.68.

Humana Stock Down 1.7 %

HUM stock opened at $290.52 on Thursday. The firm has a market cap of $34.98 billion, a PE ratio of 25.73, a P/E/G ratio of 2.21 and a beta of 0.56. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. The firm’s fifty day moving average is $275.13 and its 200 day moving average is $299.72. Humana Inc. has a one year low of $213.31 and a one year high of $406.46.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.